The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus

A peptide based on complementarity-determining region (CDR)-1 of a monoclonal murine anti-DNA Ab that bears the common idiotype, 16/61d, was synthesized and characterized. The peptide, designated pCDR1, was found to be an immunodominant T-cell epitope in BALB/c mice. The CDR1-based peptide was shown to be capable of inhibiting the in vivo priming of BALB/c mice immunized with the peptide or with the whole anti-DNA 16/61d(+) mAbs of either mouse or human origin. We show here that administration of pCDR1 (weekly, i.v., 100 mug/mouse) in aqueous solution for 5 weeks starting at the time of disease induction with the human 16/61d prevented the development of clinical manifestations of experimental systemic lupus erythematosus (SLE). Further, 10 weekly injections of pCDR1 to BALB/c mice with an established experimental SLE down-regulated clinical manifestations of SLE (e.g,, anti-DNA auto-Abs, leukopenia, proteinuria, immune complex deposits in the kidneys) in the treated mice. Prevention of SLE induction was shown to be associated mainly with a decrease in the levels of IL-2, INF gamma, and the proinflammatory cytokine TNF alpha. On the other hand, the secretion of the immunosuppressive cytokine TGF beta was elevated. Amelioration of the clinical manifestations of an already established experimental SLE correlated with a dramatic decrease in TNF alpha secretion, elevated levels of TGF beta, and immunomodulation of the Th1 and Th2 type cytokines to levels close to those observed in healthy mice.